Accelerating Covid vaccine development
Cloud computing has gained widespread adoption in the pharmaceutical and life science sectors. Its applications span diverse areas including expediting drug design, conducting molecular research, and performing test series analysis. An illustrative example is the utilization of cloud resources by a manufacturer involved in developing a Covid vaccine.
With a global footprint and a reputation as a leading pharmaceutical enterprise, this company has undergone a remarkable evolution. Starting as a research-centric biotech organization, it has now emerged as a fully-fledged biopharma company. Specializing in the development of a diverse portfolio of mRNA-based vaccines and therapeutics, their journey has been powered by their Research and Development division. This division leverages computational resources from multiple cloud service providers to drive their groundbreaking research initiatives, fueling innovation and shaping a brighter future.
Amidst the Covid pandemic, the company faced the urgent task of expediting the development of a vaccine. However, the complex multi-cloud ecosystem posed significant obstacles in effectively managing resources across different providers. By leveraging on-demand computing, machine learning, adaptable capacity, and real-time analytics, they heavily relied on AWS services to supercharge their R&D endeavors. Given the global nature of the vaccine development, scaling cloud resources across availability regions played a pivotal role.
The company harnessed the power of the emma platform — an enterprise multi-cloud management application — to expedite vaccine production and expand its global reach. This strategic move allowed them to fully unlock the potential of their cloud-based strategy. This enabled them to achieve remarkable scale and efficiency, with the objective of accelerating expedite vaccine production and expanding their global reach.
The emma platform played a crucial role in supporting the company’s achievements through its remarkable capabilities:
Seamless cloud resource management
The emma platform provided the company with a cohesive and efficient interface, enabling effortless distribution and management of resources across multiple cloud service providers. This functionality ensured optimal allocation, optimization, and scaling of computational resources, which greatly supported their research and vaccine development efforts.
Optimized machine learning on AWS
To leverage the power of machine learning techniques on AWS for mRNA-COVID-19 vaccine sequencing, a robust infrastructure was required. The emma platform efficiently configured and managed these resources, enabling the company to swiftly develop and fine-tune their machine learning models for vaccine sequencing.
Rapid deployment and scaling
With the platform's exceptional agility and scalability, the company was able to quickly deploy and scale their resources to meet the demands of the urgent COVID vaccine development project. This rapid response was instrumental in achieving the sequencing milestone with minimal delay.
Integration of artificial intelligence
The emma platform seamlessly integrates with artificial intelligence algorithms, significantly enhancing different aspects of drug development. By leveraging these AI algorithms, the company accelerates experimentation cycles, swiftly tests hypotheses, and fine-tunes vaccine designs at an unprecedented pace. The pivotal role of the platform in expediting the entire development process cannot be overstated.
Leveraging the cloud-agnostic approach of the emma multi-cloud management platform, the company unleashed the true potential of its cloud-based strategy. This empowered them to achieve remarkable milestones in an unprecedented timeframe. In just two days, they successfully sequenced their mRNA-COVID-19 vaccines using cutting-edge machine learning techniques developed on AWS.
Merely 25 days later, the initial clinical batch was released. Moreover, artificial intelligence algorithms played a pivotal role in their drug development process—enabling rapid experimentation cycles, supporting the design of mRNA and DNA sequences, and automating quality control analyses.
This automation not only saved countless hours that would have been spent on manual reviews but also sparked significant improvements in logistics and production efficiency.
In summary, the company's ability to swiftly develop and globally scale the production of an effective COVID-19 vaccine was driven by the rapid and efficient management of their multi-cloud environment, made possible by the emma multi-cloud management platform.
Thank you for getting in touch!
We have received your details and one of our cloud experts will contact you as soon as possible
